Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells.

Shetty V, Nickens Z, Testa J, Hafner J, Sinnathamby G, Philip R.

J Proteomics. 2012 Jun 18;75(11):3270-90. doi: 10.1016/j.jprot.2012.03.044. Epub 2012 Apr 3.

PMID:
22504797
2.

MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.

Shetty V, Sinnathamby G, Nickens Z, Shah P, Hafner J, Mariello L, Kamal S, Vlahović G, Lyerly HK, Morse MA, Philip R.

J Proteomics. 2011 May 1;74(5):728-43. doi: 10.1016/j.jprot.2011.02.020. Epub 2011 Mar 11.

PMID:
21362506
3.

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R.

Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7.

4.

MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R.

PLoS One. 2012;7(11):e48484. doi: 10.1371/journal.pone.0048484. Epub 2012 Nov 7.

5.
6.

Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.

Chappell NP, Teng PN, Hood BL, Wang G, Darcy KM, Hamilton CA, Maxwell GL, Conrads TP.

J Proteome Res. 2012 Sep 7;11(9):4605-14. doi: 10.1021/pr300403d. Epub 2012 Aug 28.

PMID:
22900918
7.

Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.

Philip R, Murthy S, Krakover J, Sinnathamby G, Zerfass J, Keller L, Philip M.

J Proteome Res. 2007 Jul;6(7):2509-17. Epub 2007 Jun 5.

8.

Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.

Aggarwal S, He T, Fitzhugh W, Rosenthal K, Feild B, Heidbrink J, Mesmer D, Ruben SM, Moore PA.

Gynecol Oncol. 2009 Dec;115(3):430-7. doi: 10.1016/j.ygyno.2009.08.031. Epub 2009 Oct 2.

PMID:
19800108
9.

Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines.

Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV.

Clin Cancer Res. 2003 Jul;9(7):2778-85.

10.

[Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].

Yan XD, Pan LY.

Zhonghua Fu Chan Ke Za Zhi. 2006 Sep;41(9):584-7. Chinese.

PMID:
17181965
11.

Cut and trim: generating MHC class I peptide ligands.

Yewdell JW, Bennink JR.

Curr Opin Immunol. 2001 Feb;13(1):13-8. Review.

PMID:
11154911
12.

PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.

Musiani D, Hammond DE, Cirillo L, Erriquez J, Olivero M, Clague MJ, Di Renzo MF.

J Proteome Res. 2014 Nov 7;13(11):4970-82. doi: 10.1021/pr500651n. Epub 2014 Aug 15.

13.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
14.

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.

Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.

Clin Cancer Res. 2008 Nov 1;14(21):6924-32. doi: 10.1158/1078-0432.CCR-07-5189.

15.

Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.

Britten RA, Hardy C, Vlahou A, Gregory B, Giri PS, Drake R.

Oncol Rep. 2005 Nov;14(5):1323-30.

PMID:
16211304
16.

Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.

Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J, Wani AA.

Mol Cancer. 2011 Mar 8;10:24. doi: 10.1186/1476-4598-10-24.

18.

Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.

Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK.

Crit Rev Immunol. 2007;27(5):485-93. Review.

PMID:
18197809
19.

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.

Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.

J Ovarian Res. 2014 Apr 9;7:38. doi: 10.1186/1757-2215-7-38.

20.

Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.

Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.

J Immunol. 2001 Mar 1;166(5):3564-73.

Supplemental Content

Support Center